CMBA
FATE icon

C.M. Bidwell & Associates’s Fate Therapeutics FATE Stock Holding History

C.M. Bidwell & Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30
Closed -$49 – 472
2024
Q4 		$49 Hold
30
– – ﹤0.01% 484
2024
Q3 		$105 Hold
30
– – ﹤0.01% 498
2024
Q2 		$98 Hold
30
– – ﹤0.01% 473
2024
Q1 		$220 Hold
30
– – ﹤0.01% 474
2023
Q4 		$112 Hold
30
– – ﹤0.01% 486
2023
Q3 		$64 Hold
30
– – ﹤0.01% 517
2023
Q2 		$143 Sell
30
-24,578
-100% -$136K ﹤0.01% 502
2023
Q1 		$140K Buy
24,608
+24,479
+18,976% +$148K 0.11% 174
2022
Q4 		$1.3K Buy
129
+99
+330% +$1.86K ﹤0.01% 473
2022
Q3 		$1K Hold
30
– – ﹤0.01% 454
2022
Q2 		$1K Hold
30
– – ﹤0.01% 461
2022
Q1 		$1K Buy
+30
New +$1.16K ﹤0.01% 499

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

C.M. Bidwell & Associates's FATE Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 30 shares — an estimated $49 sold.

C.M. Bidwell & Associates first reported a position in FATE in Q1 2022 and held it in 12 quarters. The position peaked at $140K in Q1 2023. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • C.M. Bidwell & Associates reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 30 Fate Therapeutics shares in Q1 2025, an estimated $49.
  • C.M. Bidwell & Associates first reported a position in Fate Therapeutics in Q1 2022 and held it in 12 quarters.
  • C.M. Bidwell & Associates's Fate Therapeutics position peaked at $140K in Q1 2023.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.